Significance of post-progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Yano Y, Yamamoto A, Minami A, Momose K, Mimura T, Kim SK, Hayashi H, Kado T, Hirano H, Hirohata S, Yoon S, Nishi K, Tei H, Tanaka H, Oouchi S, Matsuura T, Yasutomi E, Hatazawa Y, Shiomi Y, Ueda Y, Kodama Y; Kobe Liver Conference (KLC).
Yano Y, et al. Among authors: oouchi s.
JGH Open. 2022 May 25;6(6):427-433. doi: 10.1002/jgh3.12772. eCollection 2022 Jun.
JGH Open. 2022.
PMID: 35774348
Free PMC article.